Asieris Pharmaceuticals and Uroviu announce strategic collaboration to further develop integrated diagnosis and treatment for bladder cancer
James Spargo | May 18, 2023 | News story | Research and Development | Asieris Pharmaceuticals, Diagnostics, Oncology, Uroviu, bladder cancer, oncology
US-based biopharmaceutical company Asieris Pharmaceuticals and single-use endoscopic platform creator Uroviu have announced that they have entered into a strategic collaboration to integrate the detection and treatment of bladder cancers.
As part of the collaboration, Asieris will obtain exclusive global rights to Uroviu’s patented portable single-use cystoscope, which it will use in combination with optical imaging agents to research the application of non-white light imaging technology in the diagnosis and postoperative monitoring of non-muscle invasive bladder cancer (NMBC). Asieris will also be responsible for the global commericalisation of Uroviu’s single-use cystoscope.
In 2021, the companies entered into a cooperation agreement where Asieris gained the exclusive registration and commercialisation rights of Uroviu’s single-use flexible white light cystoscopy system in mainland China, Taiwan, Hong Kong and Macau.
Dr Susan Wang, senior VP of Global Business Development and Strategic Partnership of Asieris, stated: “There is still a huge unmet need for more accessible and safer fluorescent cystoscopy in the diagnosis and surveillance of bladder cancer. We are thrilled to deepen and expand our collaboration with UroViu which enables us not only to broaden our technology portfolio, but also to expedite the implementation of Asieris’ integrated strategy for bladder cancer diagnosis and treatment, aiming to provide more effective disease management options for bladder cancer patients.”
Bruce OuYang, founder and CEO of UroViu, commented: “We are excited about the possibilities that our expanded partnership with Asieris will create. Our unique and expanding portfolio of single use endoscopic products are fulfilling UroViu’s promise to greatly improve both the patient and provider experience and elevate the standard of care in a field with rapidly advancing technologies.”
James Spargo
Related Content
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
Pharma&’s ovarian cancer therapy approved for use by NHS Scotland
Pharma& has announced that its treatment for ovarian cancer, Rubraca (rucaparib), has been accepted by …
Bio-Rad signs exclusive European distribution deal with Gencurix for oncology testing kits
The agreement expands access to oncology testing kits across Europe
